Benzinga | Dec 7, 2020 04:32PM EST

GlycoMimetics Reports New Supportive Efficacy Data For The Company's Rivipansel in Sickle Cell Acute Vaso-Occlusive Crisis Presented at 62nd ASH Annual Meeting and Exposition

Open label study demonstrated statistically significant effects of early treatment with rivipansel on time to discharge and time to discontinuation of intravenous opioids

Benefit of early intervention with E-selectin antagonist in acute VOC now reproduced in independent, contemporaneous dataset that includes both the all-ages and pediatric populations

Company expects to initiate Investigational New Drug-enabling work with GMI-1687 during 2021